IGF-I, VEGF and bFGF as predictive factors for the onset of retinopathy of prematurity (ROP);IGF-I, VEGF Y bFGF, como factores pronósticos de la aparición de la retinopatía de la prematuridad

Archivos de la Sociedad Espanola de Oftalmologia

Volumn 81, Issue 11, 2006, Pages 641-646

  Villegas Becerril, Enrique ^a,b   Gonzalez Fernandez R ^a   Perula Torres, L ^a   Gallardo Galera, J M ^a  

^a Anatomía Patológica del Hospital Reina Sofía de Tudela   (Bulgaria)

^b HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

bFGF; Citokines; Growth factor; IGF I; Retinopathy of prematurity; VEGF

Indexed keywords

FIBROBLAST GROWTH FACTOR 2; SOMATOMEDIN C; VASCULOTROPIN A;

ARTICLE; BLOOD; HUMAN; MULTIVARIATE ANALYSIS; NEWBORN; PREDICTION AND FORECASTING; RETROLENTAL FIBROPLASIA;

FIBROBLAST GROWTH FACTOR 2; HUMANS; INFANT, NEWBORN; INSULIN-LIKE GROWTH FACTOR I; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; RETINOPATHY OF PREMATURITY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 37749019322     PISSN: 03656691     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Neely KA, Gardner TW. Ocular neovascularization: clarifying complex interactions. Am J Pathol 1998; 153: 665-670.
2. Hellstrom A, Engstrom E, Hard AL, Albertsson-Wikland K, Carlsson B, Niklasson A, et al. Postnatal serum insulin-like growth factor I deficiency is associated with retinopathy of prematurity and other complications of premature birth. Pediatrics 2003; 112: 1016-1020.
3. Villegas Becerril E, Fernández Molina F, Gonzalez R, Gallardo Galera JM. Valores de IGF-I séricos en la ROP. Buscando nuevas indicaciones para su screening. Arch Soc Esp Oftalmol 2005; 80: 233-238.
4. Mesiano S, Ferrara N, Jaffe RB. Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am J Pathol 1998; 153: 1249-1256.
5. Jakeman LB, Armanini M, Phillips HS, Ferrara N. Developmental expression of binding sites and messenger ribonucleic acid for vascular endothelial growth factor suggests a role for this protein in vasculogenesis and angiogenesis. Endocrinology 1993; 133: 848-859.
6. McColm JR, Geisen P, Hartnett ME. VEGF isoforms and their expression after a single episode of hypoxia or repeated fluctuations between hyperoxia and hypoxia: relevance to clinical ROP. Mol Vis 2004; 10: 512-520.
7. Ozaki H, Okamoto N, Ortega S, Chang M, Ozaki K, Sadda S, et al. Basic fibroblast growth factor is neither necessary nor sufficient for the development of retinal neovascularization. Am J Pathol 1998; 153: 757-765.
8. Boulton M, Gregor Z, McLeod D, Charteris D, Jarvis-Evans J, Moriarty P, et al. Intravitreal growth factors in proliferative diabetic retinopathy: correlation with neovascular activity and glycaemic management. Br J Ophthalmol 1997; 81: 228-233.
9. Lashkari K, Hirose T, Yazdany J, McMeel JW, Kazlauskas A, Rahimi N. Vascular endothelial growth factor and hepatocyte growth factor levels are differentially elevated in patients with advanced retinopathy of prematurity. Am J Pathol 2000; 156: 1337-1344.
10. American Academy of Pediatrics. Section on Ophthalmology. Screening examination of premature infants for retinopathy of prematurity. Pediatrics 2001; 108: 809-811.
11. Section on Ophthalmology American Academy of Pediatrics; American Academy of Ophthalmology; American Association for Pediatrics Ophthalmology and Strabismus. Screening examination of premature infants for retinopathy of prematurity. Pediatrics 2006; 117: 572-576.
12. Palmer EA, Flynn JT, Hardy RJ, Phelps DL, Phillips CL, Schaffer DB, et al. Incidence and early course of retinopathy of prematurity. The Cryotherapy for Retinopathy of Prematurity Cooperative Group. Ophthalmology 1991; 98: 1628-1640.
13. de la Cruz Bertolo FJ, Pallas Alonso CR, Tejada Palacios P. Screening for retinopathy of prematurity: reliability. An Esp Pediatr 1999; 50: 156-160.
14. Good WV; Early Treatment for Retinopathy of Prematurity Cooperative Group. Final results of the Early Treatment for Retinopathy of Prematurity (ETROP) randomized trial. Trans Am Ophthalmol Soc 2004; 102: 233-248.
15. Schulenburg WE, Bloom PA. Current problems in the management of ROP. Acta Ophthalmol Scand Suppl 1995; 214: 14-16.
16. Goble RR, Jones HS, Fielder AR. Are we screening too many babies for retinopathy of prematurity? Eye 1997; 11: 509-514.
17. Fielder AR, Haines L, Scrivener R, Wilkinson AR, Pollock JI; Royal Colleges of Ophthalmologists and Paediatrics and Child Health, and the British Association of Perinatal Medicine. Retinopathy of prematurity in the UK II: audit of national guidelines for screening and treatment. Eye 2002; 16: 285-291.
18. Hutchinson AK, Saunders RA, O'Neil JW, Lovering A, Wilson ME. Timing of initial screening examinations for retinopathy of prematurity. Arch Ophthalmol 1998; 116: 608-612.
19. Pallás Alonso CR, Tejada Palacios P, Medina López MC, Martín Puerto MJ, Orbea Gallardo C, Barrio Andrés MC. Retinopatía del prematuro: Nuestra experiencia. An Esp Pediatr 1995; 42: 52-56.
20. Slevin M, Murphy JF, Daly L, O'Keefe M. Retinopathy of prematurity screening, stress related responses, the role of nesting. Br J Ophthalmol 1997; 81: 762-764.
21. Rush R, Rush S, Nicolau J, Chapman K, Naqvi M. Systemic manifestations in response to mydriasis and physical examination during screening for retinopathy of prematurity. Retina 2004; 24: 242-245.
22. Villegas Becerril E, Gonzalez Fernandez R, Fernandez Molina F, Gallardo Galera JM. Growth factor levels and ROP. Ophthalmology 2005; 112: 2238.